FFA
CUE icon

Farther Finance Advisors’s Cue Biopharma CUE Stock Holding History

Farther Finance Advisors’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1
Closed -$44 – 4026
2024
Q2 		$44 Buy
+1
New +$49 ﹤0.01% 3705
2024
Q1 		– Sell
-1
Closed -$58 – 3622
2023
Q4 		$58 Buy
+1
New +$71 ﹤0.01% 3359

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
GLA
Good Life Advisors Reading, Pennsylvania $1.6B AUM 15.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Farther Finance Advisors's CUE Position: Q3 2024 in Review

Farther Finance Advisors sold out of Cue Biopharma (CUE) in Q3 2024, closing a stake of 1 share — an estimated $44 sold.

Farther Finance Advisors first reported a position in CUE in Q4 2023 and held it in 2 quarters. The position peaked at $58 in Q4 2023. 50 funds tracked by Wall St. Rank hold CUE as of Q3 2024.

  • Farther Finance Advisors reported no remaining Cue Biopharma position as of Q3 2024 after selling out during the quarter.
  • Farther Finance Advisors sold 1 Cue Biopharma share in Q3 2024, an estimated $44.
  • Farther Finance Advisors first reported a position in Cue Biopharma in Q4 2023 and held it in 2 quarters.
  • Farther Finance Advisors's Cue Biopharma position peaked at $58 in Q4 2023.
  • 50 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2024.

Based on Farther Finance Advisors's 13F filing for Q3 2024, filed 29 Oct 2024.